Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819425 | 0.96 | CYP19A1 (0.36) | ALDH1A1SMN1; SMN2CYP19A1LMNATSHR | |
| SCHEMBL13685702 | 0.94 | CYP19A1 (0.38) | ALDH1A1SMN1; SMN2CYP19A1LMNATSHR | |
| SCHEMBL7819937 | 0.91 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL15286438 | 0.82 | KDM4E (0.35) | ALDH1A1SMN1; SMN2ACHEBCHEKDM4E | |
| SCHEMBL23089454 | 0.81 | SCN1A (0.47) | ALDH1A1SMN1; SMN2LMNAACHEBCHE | |
| SCHEMBL29041383 | 0.77 | — | — | |
| SCHEMBL25272016 | 0.77 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2LMNAHTT | |
| Hydrochloric Acid SCHEMBL29182803 | 0.77 | ACHE (0.31) | ALDH1A1SMN1; SMN2ACHEBCHE | |
| SCHEMBL23094323 | 0.74 | CYP19A1 (0.38) | SMN1; SMN2CYP19A1NPSR1 | |
| SCHEMBL30691820 | 0.74 | CYP19A1 (0.34) | CYP19A1SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201921-A | Lactams as CBL-B inhibitors selective for C-CBL | 基因泰克公司 | 2024-06-14 | — | — | CN | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885SMN1; SMN2 4805/4885CYP19A1 2842/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | ALDH1A1 3464/4885SMN1; SMN2 2517/4885CYP19A1 1933/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | ALDH1A1 4217/4885SMN1; SMN2 4802/4885CYP19A1 3306/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ALDH1A1 3864/4885SMN1; SMN2 4805/4885CYP19A1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.